SV Health Investors is a Boston-based healthcare investment platform with a major presence across venture, growth, and specialized fund strategies. It manages dedicated pools of capital with strong healthcare focus and has built a particularly important position in neurology and neurodegeneration through vehicles such as the Dementia Discovery Fund. That specialization gives it unusual depth in brain-related healthcare.

Its broader neuroscience portfolio includes companies such as Therini Bio, Cerevance, Alector, Cumulus Neuroscience, and Caraway Therapeutics. These span diagnostics, neurodegeneration therapeutics, and related brain-health technologies, making SV Health one of the more clearly neurology-oriented institutional investors in healthcare. Its strengths lie in scientific sophistication, therapeutic depth, and long-standing sector credibility.

SV Health invests globally, with strongest focus on the US and other developed healthcare markets. For neurotech founders, it is most relevant where the company sits within neurology, neurodegeneration, or clinically serious brain-health innovation. It is especially strong for companies closer to healthcare and therapeutics than to consumer or pure hardware neurotech.